Healthcare, technology, energy, consumer goods, and more. Every day Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.
On March 8, 2018, the United States enacted 25% tariffs on imported steel. A year later, have those tariffs accomplished what they set out to do? Motley Fool Contributor Jason Hall and Industry Focus host Nick Sciple answer that question and share their favorite steel investment on this week’s episode.
Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.
Amazon has increased its focus on profitability and that means getting rid of items where it “can’t realized a profit” or CRaP as the company unofficially calls them. Host Shannon Jones and Fool Contributor Daniel Kline also discuss whether CVS selling CBD products fits its image as a company focused on health.
In the latest edition of our Between Two Fools interview series, host Jason Moser sits down with Ellevest CEO and co-founder Sallie Krawckeck. Then, Fool.com contributor Matt Frankel, CFP tells investors what they need to know about the latest Federal Reserve meeting and why bank stocks have been dropping ever since. Finally, you’ll hear which two stocks are on our watch lists this week.
Today we talk about a topic we've never covered before -- ETFs!
Exchange-traded Funds are a great way for investors to get instant exposure to a basket of companies, and there are plenty of tech funds that have put up big returns over the past few years. We run through some solid options, and explain the difference between ETFs and mutual funds.
Sometimes great companies are found in under-the-radar places. Graco is one of those companies. You probably haven’t heard of it (I thought it made baby strollers before doing my research), but this maker of industrial fluid and coating machinery has trounced Mr. Market over the past 25 years. Motley Fool Senior Analyst John Rotonti joins the podcast to discuss why this underfollowed company is an attractive investment today.
Fool's have questions, we've got answers! In today's show we offer tips on what to look for before buying clinical-stage and commercial-stage biotech stocks, including 5 checklist items you ought to know.
It’s March Madness time as the NCAA men’s and women’s basketball tournaments are set to begin. On this week’s episode of Industry Focus: Consumer Goods host Jason Moser and Fool.com contributor Asit Sharma look at how their favorite teams made it to the Big Dance and talk about all the different ways investors can benefit from one of the year’s biggest sporting events.
In the latest installment of our Between Two Fools interview series, Industry Focus: Financials host Jason Moser sits down with LivePerson (NYSE: LPSN) CEO Rob LoCascio. Plus, Wells Fargo (NYSE: WFC) CEO Tim Sloan just got a $1 million raise – did he deserve it? And, why does conglomeration seem to work so well for companies like Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) and Markel (NYSE: MKL), but not forGeneral Electric (NYSE: GE). All this and more on this week’s episode.
The original SaaS business hit a big milestone recently, we recap how the company turned CRM into a business worth over $100 billion. Then we turn our attention to a SaaS stock that's still in its early innings, Shopify.
To wrap things up, we get some tips on how to talk about money with kids from a visiting team of junior analysts.